Employee Health Abbott BinaxNOW RSV

Clinic



|  |  |
| --- | --- |
| Effective Date: November 2021 | Department: Laboratory |
| Date of Review: November 2023 | Approval: Laboratory Management |

1. **Intended Use:**

The **BinaxNOW™** RSV Card is a rapid immunochromatographic assay for the qualitative detection of respiratory syncytial virus (RSV) fusion protein antigen in nasal wash and nasopharyngeal swab specimens from symptomatic patients. This test is intended for *in vitro* diagnostic use to aid in the diagnosis of respiratory syncytial virus infections in neonatal and pediatric patients under the age of 5. Negative test results should be confirmed by cell culture or DFA.

1. **Summary and Explanation of the test:**

RSV is a common cause of upper and lower respiratory tract infections and the major cause of bronchiolitis and pneumonia in infants and children. Infections and outbreaks due to RSV typically occur yearly in the fall, winter and spring. While RSV can cause significant respiratory illness in older children and adults, the disease tends to be milder in these populations than in infants and young children.

Rapid identification and diagnosis of RSV has become more important due to the availability of effective antimicrobial therapy. Rapid identification can lead to reduced hospital stays, reduction in antimicrobial use, and reduction in the cost of hospital care.

1. **Test Principle:**

The **BinaxNOW™** RSV Card is an immunochromatographic membrane assay used to detect RSV fusion protein antigen in nasal wash and nasopharyngeal swab specimens. Anti-RSV antibody, the Sample Line, is adsorbed onto nitrocellulose membrane. Control antibody is adsorbed onto the same membrane as a second stripe. Both anti-RSV and control antibodies are conjugated to visualizing particles that are dried onto an inert fibrous support. The resulting conjugate pad and the striped membrane are combined to construct the test strip. This test strip is mounted on the right side of a cardboard, book shaped hinged test card.

Swab samples (controls and patients) require a preparation step, in which the sample is eluted off the swab into an appropriate solution. Nasal wash samples do not require any preparation.

To perform the test, the sample to be tested is added to the white pad at the top of the test strip, and the test card is closed. RSV antigen present in the sample reacts to bind anti-RSV conjugated antibody. The resulting antigen-conjugate complexes are captured by immobilized anti-RSV antibody, forming the Sample Line. Immobilized Control Line antibody captures a visualizing conjugate, forming a pink Control Line. The Control Line is blue in a card that has not been tested.

Test results are interpreted by the presence or absence of visually detectable pink-to-purple colored lines. A positive test result, read at 15 minutes, will include the detection of both a Sample Line and a Control Line. A negative test result, read at 15 minutes, will produce only a Control Line, indicating that RSV antigen was not detected in the sample. Failure of the Control Line to appear, or the Control Line remaining blue, indicates an invalid assay, whether the Sample Line is present or not.

1. **SPECIMEN COLLECTION/TREATMENT**

Use fresh NP swabs and nasal washes for best test performance.

|  |  |
| --- | --- |
| **SPECIMEN:** | Acceptable: NP Swabs (Nasopharyngeal Swabs)  Nasal Washes |
| **SPECIMEN COLLECTION:** | **NP Swabs:**  Use polyester, rayon, foam, cotton and flocked flexible shaft nasopharyngeal swabs to collect NP sample. Elute swab within one hour of collection in 0.5 – 3.0 ml of a suitable transport liquid. Test as soon as possible.  **Nasal Washes:**  Collect nasal washes in standard containers. Use procedures appropriate for the age of the patient. Test as soon as possible. |
| **HANDLING/STORAGE/**  **TRANSPORT:** | **NP Swabs:**  Elute swab within one hour of collection in 0.5 - 3.0 ml of a suitable transport liquid. Test as soon as possible. Eluted swab samples can be held at 15-30˚C for up to 4 hours before testing. Eluted swabs can be held at 2-8˚C for up to 48 hours before testing. Allow samples to warm to room temperature before testing. Swirl gently to mix before testing.  **Nasal Washes:**  Washes can be held at 15-30˚C for up to 4 hours, or at 2-8˚C for up to 24 hours, before testing.  Washes can be put in up to 3.0 ml of a suitable transport liquid before testing. Doing so will dilute wash samples. This dilution may result in test sensitivity that is lower than that shown in this insert.  Allow samples to warm to room temperature before testing. Swirl gently to mix before testing.  If needed, transport sample at 2-8˚C in a leak proof container. |
| **TRANSPORT MEDIA:** | The following transport media were tested and are acceptable for use in the **BinaxNOW™** RSV Card.   |  |  | | --- | --- | | Amies Media | Brain Heart Infusion Broth | | Dulbecco Medium | Hank’s Balanced Salt Solution | | M4 Media | M4-RT Media | | M5 Media | Phosphate Buffer Solution | | Saline | Stuart’s Media | | Tryptose Phosphate Broth | UTM-RT Media | | Veal Infusion Broth | | |
| **HANDLING PRECAUTIONS** | Patient samples, controls and test devices should be handled as though they could transmit disease. Observe established precautions against microbial hazards. |

1. **REAGENTS AND MATERIALS**

**Materials Provided**

|  |  |  |
| --- | --- | --- |
| **COMPONENT** | **CONTENT** | **QUANTITY** |
| **TEST CARDS** | |  | | --- | | A membrane coated with mouse antibody specific for RSV antigen and with control line antibody is combined with mouse anti-RSV and control line antibody conjugates in a hinged test card. The membrane of an untested card contains a blue line at the control line area. | | 10/22 |
| **TRANSFER PIPETTES** | Fixed volume (100 μl) transfer pipettes used to transfer sample to the test cards. Use only pipettes provided by or a calibrated pipette capable of delivering 100 μl sample volume. | 10/22 |
| **POSITIVE CONTROL SWAB** | Inactivated RSV dried onto swab. | 1 |
| **NEGATIVE CONTROL SWAB** | Inactivated *Streptococcus* Group A dried onto swab. | 1 |
| **ELUTION SOLUTION VIALS FOR CONTROL SWABS/SWAB SPECIMENS** | Vials containing elution solution used to prepare the Control Swabs/Swab Specimens for testing. Do not use other elution solutions with the **BinaxNOW™** RSV Card Control Swabs. | 10/22 |
| **NP SWABS** | Sterile swabs for use in the **BinaxNOW™** RSV Card. | 10/22 |

1. **Materials Recommended But Not Provided**

* Clock, timer, or stopwatch
* Nasal wash collection containers

1. **STORAGE AND STABILITY**

Store at 2-30˚C. The **BinaxNOW™** RSV Card kit and reagents are stable until the expiration date printed on the kit box.

1. **QUALITY CONTROL**

**Daily Quality Control:**

The **BinaxNOW™** RSV Card has built-in procedural controls. For daily quality control, suggests that you record these controls for each test run.

**Procedural Controls:**

1. An untested card has a blue line at the “Control” position. If the test has been done correctly and the reagents flow, this blue line will always turn pink in a tested card.
2. The clearing of background color from the result window is a negative background control. The background color in the window should be light pink to white within 15 minutes. Background color should not interfere with the reading of the test.

**External Positive and Negative Controls:**

Good laboratory practice suggests the use of positive and negative controls to guarantee that:

* test reagents are working; and
* the test is correctly performed.

**BinaxNOW™** RSV Card kits contain Positive and Negative Control Swabs. These swabs will check for substantial reagent failure. The Positive Control will not ensure precision at the assay cut-off. Test these swabs once with each new shipment received. Other controls may be tested in order to conform with:

* local, state and/or federal regulations,
* accrediting groups, and/or,
* your lab’s standard QC procedures.

Refer to 42 CFR 493.1256 for help on proper QC techniques (U.S. customers only). If the correct control results are not obtained, do not report patient results. Contact Technical Service during normal business hours.

1. **PRECAUTIONS**
2. For *in vitro* diagnostic use.
3. Leave test sealed in its foil pouch until just before use.
4. Do not use kit past its expiration date.
5. Do not mix components from different kit lots.
6. The white sample pad at the top of the test strip contains reagents that extract the target antigen from the virus. To ensure optimum performance, add the sample **SLOWLY** (drop by drop) to the **MIDDLE** of this pad such that all of the sample volume (100 µl) absorbs into the pad. **DO NOT** add sample to the pink/purple pad.
7. The RSV Positive Control Swab has been prepared from RSV-infected tissue culture cells that have been inactivated and subsequently tested by bioassay procedures. Use universal precautions when performing the assay. Samples may be infectious. Proper handling and disposal methods should be established according to local, state, and federal regulations.
8. **INVALID RESULTS** can occur when an insufficient volume of specimen is added to the test card. To ensure delivery of an adequate volume (100 μl), make certain that the lower shaft of the transfer pipette is full and does not contain air spaces before dispensing contents of the pipette onto the Sample Pad of the card. If air spaces are present, expel the specimen back into the container by squeezing the top bulb and redraw the specimen into the pipette. Use a new pipette if necessary.
9. When testing nasal wash samples, avoid viscous areas of the sample when drawing specimen into the transfer pipette. If the pipette becomes clogged, such that the lower shaft of the pipette is not full, expel the specimen back into container by squeezing the top bulb and redraw the specimen into the pipette. Use a new pipette if necessary.
10. Polyester, rayon, foam, cotton and flocked flexible shaft nasopharyngeal swabs, have been evaluated and found to be acceptable for use in the **BinaxNOW™** RSV Card. Do not use calcium alginate nasopharyngeal swabs in the **BinaxNOW™** RSV Card.
11. All transfer pipettes and elution solution vials are single use items – do not use with multiple specimens.
12. Elution solution contains Triton® X-100 and ProClin® 300. Warning. Causes serious eye irritation. 
13. Safety Data Sheets for this product are available upon request.
14. Follow your national, regional, and local ordinances accordingly for waste disposal regulations.
15. **SAMPLE AND CONTROL SWAB PREPARATION PROCEDURE**

**Nasal Washes:**

Nasal wash samples do not need preparation. Go to Test Procedure.

**Nasopharyngeal Swabs:**

Remove sample from swab in 0.5-3.0 ml of saline or media by rotating swab in the liquid. Go to Test Procedure. To use **BinaxNOW™** Elution Solution to elute swab, follow the Control Swab procedure below. Refer to Specimen Collection and Handling section (in the product instructions or Specimen Collection/Treatment section in this packet) for approved list of Transport Media.

**Control Swabs:**

|  |  |  |
| --- | --- | --- |
|  | 1. The test kit contains test vials pre-filled with elution solution. Twist off the test vial cap.  2. Put the swab to be tested into test vial. Rotate the swab vigorously (without making a lot of bubbles) three (3) times in the liquid.  3. Press the swab against the side of the vial and turn as you remove it from the vial. This removes sample from the swab.  4. Discard the swab.  5. Test the liquid sample (from the test vial) in the **BinaxNOW™** RSV Card as soon as possible. Go to Test Procedure. |  |

1. **TEST PROCEDURE**

***WARNING:*** INVALID RESULTS can occur when too little sample is added to the test. Be sure that the lower part of the transfer pipette is full and does not have any air spaces before you add the sample to the Sample Pad. If there are air spaces, put the sample back into the container by squeezing the top bulb. Redraw the sample from the bottom of the container into the pipette. Use a new pipette if needed.

|  |  |
| --- | --- |
| **1.** Remove card from the pouch just prior to testing and lay flat on work bench.  **2.** Fill pipette by firmly squeezing the top bulb and then placing pipette tip into sample. Slowly release bulb while tip is still in sample. This will pull liquid into the pipette. Make sure there are no air spaces in the lower part of the pipette.  **3.** See arrow on test card to find the **WHITE** sample pad at the top of the test strip. **SLOWLY** (drop by drop) add entire contents of the pipette (100 μl) to the **MIDDLE** of this pad by squeezing the top bulb such that all of the sample volume absorbs into this pad. **DO NOT** add sample to the pink/purple colored pad.  **4.** Immediately peel off adhesive liner from the test card. Close and securely seal the card. Read result in window 15 minutes after closing the card. |  |

***Note:*** *Read test results under good lighting conditions. If necessary tilt the card to reduce glare on the result window.*

1. **INTERPRETATION OF TEST RESULTS**

*Note: Do not read test results before or after 15 minutes as they may not be correct.*

|  |  |
| --- | --- |
| For a **NEGATIVE SAMPLE**, the BLUE Control Line in the lower half of the window turns a PINK to PURPLE color. No other line appears. |  |
| For a **POSITIVE SAMPLE**, the BLUE Control Line turns a PINK TO PURPLE color. A second PINK TO PURPLE Sample Line appears above it. Any Sample Line, even when very faint, is positive. |  |
| A test is **INVALID** if the Control Line remains blue or is not present at all, whether a Sample line is present or not. Repeat an invalid test with a new test card. If the repeat test is also invalid, do not report test results. Call Technical Service during normal business hours. |  |

1. **REPORTING OF RESULTS**

|  |  |
| --- | --- |
| **RESULT** | **SUGGESTED REPORT** |
| **POSITIVE** | Positive for RSV antigen. A positive result may occur without the presence of live virus. |
| **NEGATIVE** | Negative for RSV antigen. Infection due to RSV cannot be ruled out. The antigen in the sample may be below the detection limit of the test. Negative test results should be confirmed by cell culture or DFA. |

Notify Technical Service of any performance, perceived or validated, that does not meet test specifications described in the product insert (or this packet).

1. **LIMITATIONS**
2. A negative test result does not exclude infection with RSV nor is it intended to rule out other microbial-caused respiratory infections. Therefore, the results obtained with the **BinaxNOW™** RSV Card should be used in conjunction with clinical findings to make an accurate diagnosis.
3. The **BinaxNOW™** RSV Card detects both viable and non-viable RSV. Test performance depends on antigen load in the specimen and may not correlate with cell culture performed on the same specimen.
4. Inadequate specimen collection or low levels of virus shedding may result in suboptimal performance and may yield false negative results.
5. **BinaxNOW™** RSV Card performance has not been evaluated in patients who have been treated with palivizumab. However, an analytical study has demonstrated that palivizumab interferes with the ability of the **BinaxNOW™** RSV Card to detect RSV.
6. The potential for interference from anti-microbials and interferon has not been established. Monoclonal antibodies may not detect all antigenic variants or new strains of RSV.
7. **EXPECTED VALUES**

The prevalence of RSV varies from year to year, with outbreaks typically occurring during the fall and winter months. The rate of positivity found in RSV testing is dependent on many factors including the method of specimen collection, the test method used, geographic location, and the disease prevalence in specific localities. In the 2002 clinical study, the average prevalence of RSV was 2% in wash samples and 4% in nasopharyngeal swab samples. Prevalence of RSV in nasopharyngeal swab samples collected during the 2003 clinical study was 21%.

1. **PERFORMANCE CHARACTERISTICS**

**ANALYTIC STUDIES**

**Analytical Reactivity:**

There are 2 known subgroups of respiratory syncytial virus (RSV) and both contain the conserved fusion protein targeted by the **BinaxNOW™** RSV Card.2 Six (6) subgroup A clinical isolates and five (5) subgroup B clinical isolates tested positive in the **BinaxNOW™** RSV Card at concentrations ranging from 1.56 x 10-1 TCID50/ml to 5.00 x 104 TCID50/ml.

*Note: The reported TCID50/ml levels are dependent on a number of factors including the cell culture lines used, the number of passages performed and the efficiencies of the various isolates.*

**Analytical Specificity (Cross-Reactivity):**

To determine the analytical specificity of the **BinaxNOW™** RSV Card, 48 commensal and pathogenic microorganisms (28 bacteria and 20 viruses) that may be present in the nasal cavity or nasopharynx were tested. All of the following microorganisms were negative when tested at concentrations greater than 1 x 105

TCID50/ml (viruses) or greater than 1 x 108 organisms/ml (bacteria). Metapneumovirus was tested at 2 x 103 TCID50/ml and did not cross-react.

|  |  |
| --- | --- |
| **BACTERIA** | **VIRUSES** |
| |  |  | | --- | --- | | *Acinetobacter* |  | | Adenovirus 5\* |
| *Bordetella pertussis* | Adenovirus 7\* |
| *Candida albicans* | CMV\* |
| *Enterococcus faecalis* | Coronavirus\* |
| *Escherichia coli* | Coxsackie B4\* |
| *Gardnerella vaginalis* | Influenza A 2 / Japan / 305 / 57 |
| *Haemophilus influenza* | Influenza A / Hong Kong / 8 / 68 |
| *Klebsiella pneumonia* | |  | | --- | | Influenza A / Aichi / 68 | |
| *Lactobacillus casei* | Influenza A / PR / 8 / 34 |
| *Legionella pneumophila* | Influenza A / Victoria / 3 / 75 |
| *Listeria monocytogenes* | |  | | --- | | Influenza A 1 / FM / 1 / 47 | |
| *Moraxella catarrhalis* | |  | | --- | | Influenza B Allen / 45 | |
| *Neisseria gonorrhoeae* | Influenza B Lee / 40 |
| *Neisseria meningitidis* | Influenza B Mass / 3 / 66 |
| *Neisseria sicca* | |  | | --- | | Influenza B Maryland / 1 / 59 | |
| *Neisseria subflava* | |  | | --- | | Influenza B Taiwan / 2 / 62 | |
| *Proteus vulgaris* | Metapneumovirus |
| *Pseudomonas aeruginosa* | Parainfluenza 1\* |
| *Serratia marcescens* | Parainfluenza 2\* |
| *Staphylococcus aureus* | Parainfluenza 3\* |
| |  | | --- | | *Staphylococcus aureus* (Cowan protein A producing strain) | |  |
| *Staphylococcus epidermidis* |  |
| *Streptococcus,* Group A |  |
| *Streptococcus,* Group B |  |
| *Streptococcus,* Group C |  |
| *Streptococcus,* Group F |  |
| *Streptococcus mutans* |  |
| *Streptococcus pneumoniae* |  |

\*These viral strains were obtained from American Type Culture Collection (ATCC) with titer information, and the titers were not verified by Abbott.

1. **Interfering Substances**

The following substances, naturally present in respiratory specimens or that may be artificially introduced into the nasal cavity or nasopharynx, were evaluated in the **BinaxNOW™** RSV Card at the concentrations listed and were found not to affect test performance.

|  |  |  |  |
| --- | --- | --- | --- |
| **SUBSTANCE** | **CONCENTRATION** | **SUBSTANCE** | **CONCENTRATION** |
| Whole blood | 2% | Diphenhydramine | 5 mg/ml |
| 3 OTC mouthwashes | 25% | Guaiacol glycerol ether | 20 mg/ml |
| 3 OTC throat drops | 25% | Oxymetazoline | 10 mg/ml |
| 3 OTC nasal sprays | 25% | Phenylephrine | 100 mg/ml |
| 4-acetamidophenol | 10 mg/ml | Phenylpropanolamine | 20 mg/ml |
| Acetylsalicylic acid | 20 mg/ml | Rebetol® | 500 ng/ml |
| Albuterol | 20 mg/ml | Relenza® | 20 mg/ml |
| Chlorpheniramine | 5 mg/ml | Rimantadine | 500 ng/ml |
| Dextromethorphan | 10 mg/ml | Tamiflu® | 100 mg/ml |

**Clinical Studies:**

**Nasal Wash – Clinical Specificity (Prospective Study):**

The performance of the **BinaxNOW™** RSV Card was compared to cell culture in a multi-center study conducted during the 2002 Flu season at physician offices and clinics located throughout the United States. Nasal wash specimens were collected from children and adults presenting with RSV-like symptoms for 3 days or less and evaluated in the test. The population tested was approximately 46% female and 54% male. Patients were not included in the study if they had received an influenza vaccine within 6 months of the enrollment period, or if they had taken either an influenza or RSV medication within 30 days of the enrollment period. There were no invalid tests reported.

One hundred ninety-one (191) nasal wash specimens were tested at 4 different test sites. **BinaxNOW™** RSV Card overall specificity was 98%, and overall test agreement was 98%. Ninety-five percent (95%) confidence intervals are listed below.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | |  | | | **WASH** | | | |
|  | |  | | | **VIRAL CULTURE** | | | |
|  | | | | | **+** | | **-** |
| **BINAXNOW™ RSV CARD** | | | | **+** | 3 | | 3 |
| **RESULT** | | | | **-** | 1 | | 184 |
|  |  | |  | | | **95% CI** | | | |
| **SPECIFICITY** | = | | 98% (184/187) | | | (95.4% - 99.4%) | | | |
| **OVERALL AGREEMENT** | = | | 98% (187/191) | | | (94.7% - 99.1%) | | | |

The **BinaxNOW™** RSV Card performed similarly at the 4 test sites as shown in the table below.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **POSITIVE POINTS** | **SPECIFICITY** | | |
|  | **BinaxNOW™**  **RSV Card / Culture** | **BinaxNOW™ RSV Card / Culture** | **%** | **95% CI** |
| **SITE 1** | 1/1 | 91/94 | 97% | 91.1 - 98.8 |
| **SITE 2** | 2/3 | 83/83 | 100% | 95.7 - 100 |
| **SITE 3** | 0/0 | 6/6 | 100% | 59.0 - 99.6 |
| **SITE 4** | 0/0 | 4/4 | 100% | 47.8 - 99.5 |

**Nasal Wash - Clinical Sensitivity and Specificity (Retrospective Study):**

Since there were a low number of positive culture confirmed RSV infections generated during the prospective study, a retrospective study was conducted as follows. Nasal wash specimens from 47 viral culture positive RSV patients and 12 viral culture negative RSV patients were evaluated in the **BinaxNOW™** RSV Card. All of the samples were obtained from a large university medical center and had been collected from patients living in the northeastern region of the US. The population tested was approximately 49% male and 51% female.

**BinaxNOW™** RSV Card sensitivity was 89%, while test specificity was 100%. Overall test agreement was 92%. Ninety-five percent (95%) confidence intervals are listed below.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | | | | **WASH** | | |
| **VIRAL CULTURE** | | |
| **+** | **-** | |
| **BINAXNOW™ RSV CARD** | | | | **+** | | 42 | 0 | |
| **RESULT** | | | | **-** | | 5 | 12 | |
|  |  | |  | | **95% CI** | | |
| **SENSITIVITY** | | = | 89% (42/47) | | (77.3% - 95.3%) | | |
| **SPECIFICITY** | | = | 100% (12/12) | | (75.3% - 99.8%) | | |
| **OVERALL AGREEMENT** | | = | 92% (54/59) | | (81.6% - 96.2%) | | |

**Nasopharyngeal Swab - Sensitivity and Specificity (Prospective Study):**

The performance of the **BinaxNOW™** RSV Card on nasopharyngeal swab specimens was compared to cell culture/DFA in a multi-center US study conducted during the 2002 and 2003 flu seasons. Nasopharyngeal swab specimens were collected from children presenting with RSV or flu-like symptoms. All swab samples were placed in 0.5-3 ml of viral transport media prior to evaluation in the **BinaxNOW™** RSV Card. The population tested was 43% female and 57% male.

One hundred and seventy-nine (179) nasopharyngeal swab specimens were tested. There were no invalid tests reported. **BinaxNOW™** RSV Card sensitivity, specificity and overall agreement as compared to culture/DFA were 93%. Ninety-five percent (95%) confidence intervals are listed below.

|  |  |  |  |
| --- | --- | --- | --- |
|  | | **NASOPHARYNGEAL SWAB** | |
| **CULTURE/DFA** | |
| **+** | **-** |
| **BINAXNOW™ RSV CARD** | **+** | 25 | 10 |
| **RESULT** | **-** | 2 | 142 |

|  |  |  |  |
| --- | --- | --- | --- |
|  |  |  | 95% CI |
| Sensitivity | = | 93% (25/27) | (76.5% - 97.7%) |
| Specificity | = | 93% (142/152) | (88.3% - 96.4%) |
| Overall Agreement | = | 93% (167/179) | (88.6% - 96.1%) |

The **BinaxNOW™** RSV Card performed similarly at all test sites as shown in the tables below.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **SENSITIVITY** | | | |  | **SPECIFICITY** | | | |
| **Site** | **#** | **%** | **95% CI** |  | **Site** | **#** | **%** | **95% CI** |
| **Site 1** | 14/15 | 93 | 69.8 - 98.4 |  | **Site 1** | 69/74 | 93 | 85.1 - 97.0 |
| **Site 2** | 9/10 | 90 | 58.7 - 97.7 |  | **Site 2** | 20/23 | 87 | 67.6 - 95.3 |
| **Site 3** | 0/0 | NA | NA |  | **Site 3** | 16/18 | 89 | 66.9 - 96.6 |
| **Site 4** | 2/2 | 100 | 29.2 - 99.2 |  | **Site 4** | 37/37 | 100 | 90.7 - 99.9 |

**Reproducibility Study:**

A blind study of the **BinaxNOW™** RSV Card was conducted at 3 separate sites using panels of blind coded specimens containing negative, low positive, and moderate positive samples. Participants tested each sample multiple times on 3 different days. One hundred percent (100%) of the 234 samples tested produced the expected result yielding a 95% confidence interval of 98.4 - 100%.

**Consumer Precision Study:**

Under CLIA, Abbott conducted Consumer Precision testing at three sites using proficiency panels consisting of 210 negative, limit of detection (LOD) positive and low positive samples.

Testing was performed with liquid samples only, not with swab samples. As indicated by the overlapping 95% confidence intervals in the tables below, no significant differences were observed between the lay user and expected results, demonstrating that users with no formal laboratory training can read the package insert and perform the test with a high level of precision.

**RSV Sample Testing – Lay Users vs. Trained Laboratorians – Overall Results**

| **PARTICIPANT TYPE** | **NEGATIVE-**  **% NEGATIVE**  **(95% CI)** | **LOD -% DETECTION (95% CI)** | **LOW POSITIVE – % DETECTION (95% CI)** | **% INVALID TESTS** |
| --- | --- | --- | --- | --- |
| **Lay User** | 99% (67/68\*)  (92-100) | 97% (64/66\*)  (90-99) | 100% (67/67\*)  (95-100) | 4.3% (9/210) |
| **Trained Laboratorian** | 100% (60/60)  (94-100) | 100% (60/60)  (94-100) | 98% (59/60)  (91-100) | 0% (0/180) |

\*Invalid tests resulted in a reduced number of points graded on these sample types.

*Note: Invalid test results can occur when an insufficient volume of sample is added to the test card due to misuse of the transfer pipette. Please see the Precautions Section (note #7) and the Test Procedure section (in the product instructions or this packet) for detailed instructions on the proper use of the transfer pipette.*

**RSV Sample Testing by Site – Lay Users and Trained Laboratorians**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **SITE #** | **TOTAL # OF TESTS RUN** | **NEGATIVE-% NEGATIVE**  **(95% CI)** | **LOD -% DETECTION (95% CI)** | **LOW POSITIVE – % DETECTION (95% CI)** | **% INVALID TESTS** |
| **Lay Users** | 1 | 75 | 100% (25/25)  (87-100) | 100% (24/24\*)  (86-100) | 100% (25/25)  (87-100) | 1.3% (1/75) |
| 2 | 66 | 100% (21/21\*)  (85-100) | 100% (22/22)  (85-100) | 100% (22/22)  (85-100) | 1.5% (1/66) |
| 3 | 69 | 95% (21/22\*)  (78-99) | 90% (18/20\*)  (70-97) | 100% (20/20\*)  (84-100) | 10.1% (7/69) |
| **Trained Laboratorian** | 1 | 180 | 100% (60/60)  (94-100) | 100% (60/60)  (94-100) | 98% (59/60)  (91-100) | 0% (0/180) |

\*Invalid tests resulted in a reduced number of points generated by these sites on these sample types.

1. **REFERENCES**
2. Williams, KM, Jackson MA, Hamilton M. Rapid Diagnostic Testing for URIs in Children: Impact on Physician Decision Making and Cost. Infect. Med. 19(3): 109-111, 2002.
3. Lopez, Juan A., R. Bustos, C. Orvell, M. Berois, J. Arbiza, B. Garcia-Barreno, J. Melero. Antigenic Structure of Human Respiratory Syncytial Virus Fusion Glycoprotein. Jr. of Virology, vol. 72, no. 8, August 1998, pp. 6922-6928.